Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs

Xenobiotica

Volumn 43, Issue 11, 2013, Pages 948-955

  Nishimuta, Haruka ^a   Nakagawa, Tetsuya ^a   Nomura, Naruaki ^a   Yabuki, Masashi ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

CYP1A; CYP2C; CYP2D; CYP2J; CYP3A; Intestine; Liver; Microsomes

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 2J2; CYTOCHROME P450 3A;

ANIMAL CELL; ARTICLE; CORRELATION ANALYSIS; DOG; HUMAN; HUMAN CELL; INTESTINE; LIVER CLEARANCE; LIVER MICROSOME; MALE; METABOLISM; NONHUMAN; RAT; SPECIES DIFFERENCE;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; HUMANS; INTESTINES; LIVER; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY;

EID: 84885137659     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.787155     Document Type: Article

References (30)

1. Aiba T, Takehara Y, Okuno M, Hashimoto Y. (2003). Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats. Pharm Res 20:745-8
2. Chow T, Imaoka S, Hiroi T, Funae Y. (1999). Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver. Drug Metab Dispos 27:188-92
3. Dedrick RL. (1973). Animal scale-up. J Pharmacokinet Biopharm 1: 435-61
4. Faber MS, Jetter A, Fuhr U. (2005). Assessment of CYP1A2 activity in clinical practice: Why, how, and when? Basic Clin Pharmacol Toxicol 97:125-34
5. Hiroi T, Imaoka S, Chow T, Funae Y. (1998). Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR. Biochim Biophys Acta 1380:305-12
6. Hosea NA, Collard WT, Cole S, et al. (2009). Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-33
7. Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47: 1469-79
8. Iwatsubo T, Hirota N, Ooie T, et al. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-71
9. Komura H, Iwaki M. (2008). Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. Pharm Sci 97: 1775-800
10. Lewis DF. (2003). Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: A compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr Med Chem 10:1955-72
11. Lindell M, Lang M, Lennernäs H. (2003). Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver. Eur J Drug Metab Pharmacokinet 28:41-8
12. Lisitsa A, Archakov A, Lewi P, Janssen P. (2003). Bioinformatic insight into the unity and diversity of cytochromes P450. Methods Find Exp Clin Pharmacol 25:733-45
13. Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-94
14. Matsubara T, Kim HJ, Miyata M, et al. (2004). Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J Pharmacol Exp Ther 309:1282-90
15. Mealey KL, Jabbes M, Spencer E, Akey JM. (2008). Differential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine. Xenobiotica 38:1305-12
16. Mitschke D, Reichel A, Fricker G, Moenning U. (2008). Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats. Drug Metab Dispos 36:1039-45
17. Mordenti J. (1986). Man versus beast: Pharmacokinetic scaling in mammals. J Pharm Sci 75:1028-40
18. Nakamoto T, Oda Y, Imaoka S, et al. (1997). Effect of phenobarbital on the pharmacokinetics of lidocaine, monoethylglycinexylidide and 3- hydroxylidocaine in the rat: Correlation with P450 isoform levels. Drug Metab Dispos 1997:296-300
19. Nishimuta H, Sato K, Mizuki Y, et al. (2010). Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys. Drug Metab Dispos 38:1967-75
20. Nishimuta H, Sato K, Mizuki Y, et al. (2011). Species differences in intestinal metabolic activities of cytochrome P450 substrates between cynomolgus monkeys and humans. Drug Metab Pharmacokinet 26: 300-6
21. Pelkonen O. (2002). Human CYPs: In vivo and clinical aspects. Drug Metab Rev 34:37-46
22. Sahi J, Reyner EL, Bauman JN, et al. (2002). The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. Drug Metab Dispos 30:135-40
23. Shimada T, Mimura M, Inoue K, et al. (1997). Cytochrome P450- dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 71:401-8
24. Takara K, Ohnishi N, Horibe S, Yokoyama T. (2003). Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAs in rat small intestine. Drug Metab Dispos 31:1235-9
25. Turpeinen M, Ghiciuc C, Opritoui M, et al. (2007). Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: A comparative study in vitro. Xenobiotica 37: 1367-77
26. Wu S, Chen W, Murphy E, et al. (1997). Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272: 12551-9
27. Zhang QY, Ding X, Kaminsky LS. (1997). cDNA cloning, heterologous expression, and characterization of rat intestinal CYP2J4. Arch Biochem Biophys 340:270-8
28. Zhang Y, Yao L, Lin J, et al. (2010). Lack of appreciable species differences in nonspecific microsomal binding. J Pharm Sci 99: 3620-7
29. Zhou SF, Liu JP, Chowbay B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89-295
30. Zuber R, Anzenbacherová E, Anzenbacher P. (2002). Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6: 189-98